Merck KGaA and Inspirna Collaborate for the Development and Commercialization of Ompenaclid (RGX-202) for the Treatment of Colorectal Cancer
Shots:
- The companies have signed a licensing agreement as per which Merck KGaA will receive an exclusive license to ompenaclid outside the US along with an option to co-develop & co-promote ompenaclid in the US
- Both companies have also agreed to collaborate for the development of Inspirna’s SLC6A8 follow-on compounds for which Inspirna will retain the US co-development & co-commercialization rights
- In return Inspirna will receive an up front payment of $45M & is eligible to receive payments in development & sales based milestones for ompenaclid plus low teens tiered royalty. Moreover, Inspirna is also eligible to receive development, regulatory & sales milestone payments for each follow-on compound targeting SLC6A8 plus double-digit royalties
Ref: Merck KGaA | Image: Merck KGaA
Related News:- REGENXBIO Initiates P-I/II Trial of RGX-202 for the Treatment of Duchenne Muscular Dystrophy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
